← Eichor
Study identifier: NCT07459166 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade

Condition: Fentanyl Overdose · Fentanyl Poisoning  ·  Sponsor: Clear Scientific, Inc.

PhasePhase 2
Planned participants16
Who can joinAll sexes, 18 Years to 55 Years
Healthy volunteersYes

About this study

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CS-1103 (1,000 mg), given by intravenous (IV) infusion in healthy participants in the presence of a clinically relevant dose of fentanyl (200 μg, IV), with naloxone blockade (400 μg, IV).

This description comes directly from the study's public registry record.

Talk to the study team

Anna Del Rosario, B.S.  ·  617-621-8500  ·  adelrosario@clearsci.com

Piercen Oliver, Ph.D.  ·  617-621-8500  ·  poliver@clearsci.com

Always discuss trial participation with your own doctor first.

Locations (1)

California Clinical Trials Medical GroupGlendale, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07459166